![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ABHD8 |
Gene summary for ABHD8 |
![]() |
Gene information | Species | Human | Gene symbol | ABHD8 | Gene ID | 79575 |
Gene name | abhydrolase domain containing 8 | |
Gene Alias | ABHD8 | |
Cytomap | 19p13.11 | |
Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | B2C6G3 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
79575 | ABHD8 | LZE24T | Human | Esophagus | ESCC | 1.41e-12 | 2.32e-01 | 0.0596 |
79575 | ABHD8 | P1T-E | Human | Esophagus | ESCC | 2.88e-10 | 3.68e-01 | 0.0875 |
79575 | ABHD8 | P2T-E | Human | Esophagus | ESCC | 8.83e-12 | 1.79e-01 | 0.1177 |
79575 | ABHD8 | P4T-E | Human | Esophagus | ESCC | 6.05e-06 | 1.50e-01 | 0.1323 |
79575 | ABHD8 | P8T-E | Human | Esophagus | ESCC | 1.05e-21 | 3.21e-01 | 0.0889 |
79575 | ABHD8 | P9T-E | Human | Esophagus | ESCC | 3.19e-10 | 1.69e-01 | 0.1131 |
79575 | ABHD8 | P10T-E | Human | Esophagus | ESCC | 2.74e-29 | 4.99e-01 | 0.116 |
79575 | ABHD8 | P11T-E | Human | Esophagus | ESCC | 4.57e-13 | 3.89e-01 | 0.1426 |
79575 | ABHD8 | P12T-E | Human | Esophagus | ESCC | 3.28e-20 | 3.22e-01 | 0.1122 |
79575 | ABHD8 | P15T-E | Human | Esophagus | ESCC | 4.52e-11 | 2.23e-01 | 0.1149 |
79575 | ABHD8 | P16T-E | Human | Esophagus | ESCC | 1.67e-13 | 2.36e-01 | 0.1153 |
79575 | ABHD8 | P20T-E | Human | Esophagus | ESCC | 1.60e-03 | 5.50e-02 | 0.1124 |
79575 | ABHD8 | P21T-E | Human | Esophagus | ESCC | 5.08e-29 | 3.58e-01 | 0.1617 |
79575 | ABHD8 | P22T-E | Human | Esophagus | ESCC | 1.80e-10 | 1.35e-01 | 0.1236 |
79575 | ABHD8 | P23T-E | Human | Esophagus | ESCC | 4.45e-07 | 2.36e-01 | 0.108 |
79575 | ABHD8 | P24T-E | Human | Esophagus | ESCC | 5.78e-08 | 9.24e-02 | 0.1287 |
79575 | ABHD8 | P26T-E | Human | Esophagus | ESCC | 4.66e-40 | 2.36e-01 | 0.1276 |
79575 | ABHD8 | P27T-E | Human | Esophagus | ESCC | 5.50e-24 | 2.85e-01 | 0.1055 |
79575 | ABHD8 | P28T-E | Human | Esophagus | ESCC | 9.17e-16 | 2.32e-01 | 0.1149 |
79575 | ABHD8 | P30T-E | Human | Esophagus | ESCC | 4.05e-06 | 2.42e-01 | 0.137 |
Page: 1 2 3 4 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00086544 | Esophagus | ESCC | phospholipid biosynthetic process | 162/8552 | 253/18723 | 2.59e-09 | 5.73e-08 | 162 |
GO:00464744 | Esophagus | ESCC | glycerophospholipid biosynthetic process | 135/8552 | 211/18723 | 5.75e-08 | 1.02e-06 | 135 |
GO:00450175 | Esophagus | ESCC | glycerolipid biosynthetic process | 154/8552 | 252/18723 | 5.20e-07 | 6.96e-06 | 154 |
GO:00066446 | Esophagus | ESCC | phospholipid metabolic process | 218/8552 | 383/18723 | 5.37e-06 | 5.59e-05 | 218 |
GO:00066505 | Esophagus | ESCC | glycerophospholipid metabolic process | 174/8552 | 306/18723 | 4.92e-05 | 3.85e-04 | 174 |
GO:00066541 | Esophagus | ESCC | phosphatidic acid biosynthetic process | 26/8552 | 33/18723 | 1.06e-04 | 7.43e-04 | 26 |
GO:00464733 | Esophagus | ESCC | phosphatidic acid metabolic process | 28/8552 | 37/18723 | 2.00e-04 | 1.26e-03 | 28 |
GO:00464864 | Esophagus | ESCC | glycerolipid metabolic process | 211/8552 | 392/18723 | 6.51e-04 | 3.46e-03 | 211 |
GO:00086542 | Liver | HCC | phospholipid biosynthetic process | 150/7958 | 253/18723 | 4.77e-08 | 1.03e-06 | 150 |
GO:00066444 | Liver | HCC | phospholipid metabolic process | 214/7958 | 383/18723 | 7.25e-08 | 1.48e-06 | 214 |
GO:00550882 | Liver | HCC | lipid homeostasis | 103/7958 | 167/18723 | 4.27e-07 | 7.18e-06 | 103 |
GO:004648611 | Liver | HCC | glycerolipid metabolic process | 215/7958 | 392/18723 | 4.54e-07 | 7.49e-06 | 215 |
GO:004501711 | Liver | HCC | glycerolipid biosynthetic process | 143/7958 | 252/18723 | 3.27e-06 | 4.31e-05 | 143 |
GO:00066504 | Liver | HCC | glycerophospholipid metabolic process | 168/7958 | 306/18723 | 7.27e-06 | 8.62e-05 | 168 |
GO:004647411 | Liver | HCC | glycerophospholipid biosynthetic process | 121/7958 | 211/18723 | 9.12e-06 | 1.06e-04 | 121 |
GO:0006654 | Liver | HCC | phosphatidic acid biosynthetic process | 23/7958 | 33/18723 | 1.46e-03 | 7.75e-03 | 23 |
GO:00464732 | Liver | HCC | phosphatidic acid metabolic process | 24/7958 | 37/18723 | 5.03e-03 | 2.11e-02 | 24 |
GO:00086543 | Oral cavity | OSCC | phospholipid biosynthetic process | 130/7305 | 253/18723 | 3.96e-05 | 3.46e-04 | 130 |
GO:00464743 | Oral cavity | OSCC | glycerophospholipid biosynthetic process | 102/7305 | 211/18723 | 3.50e-03 | 1.48e-02 | 102 |
GO:00066445 | Oral cavity | OSCC | phospholipid metabolic process | 175/7305 | 383/18723 | 4.21e-03 | 1.71e-02 | 175 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ABHD8 | SNV | Missense_Mutation | novel | c.73N>A | p.Glu25Lys | p.E25K | Q96I13 | protein_coding | deleterious_low_confidence(0.02) | benign(0.079) | TCGA-90-A4EE-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | CR |
ABHD8 | SNV | Missense_Mutation | novel | c.1015N>T | p.Arg339Trp | p.R339W | Q96I13 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-CQ-A4CD-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ABHD8 | SNV | Missense_Mutation | novel | c.464A>G | p.Lys155Arg | p.K155R | Q96I13 | protein_coding | tolerated(0.05) | probably_damaging(0.978) | TCGA-CR-6474-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Unspecific | PD | |
ABHD8 | SNV | Missense_Mutation | novel | c.465N>T | p.Lys155Asn | p.K155N | Q96I13 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-CV-A463-01 | Oral cavity | head & neck squamous cell carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ABHD8 | SNV | Missense_Mutation | novel | c.769N>C | p.Phe257Leu | p.F257L | Q96I13 | protein_coding | tolerated(0.11) | benign(0.007) | TCGA-F7-A624-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ABHD8 | SNV | Missense_Mutation | novel | c.344N>T | p.Ala115Val | p.A115V | Q96I13 | protein_coding | deleterious_low_confidence(0.01) | benign(0.015) | TCGA-F7-A624-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
ABHD8 | SNV | Missense_Mutation | novel | c.394N>A | p.Ala132Thr | p.A132T | Q96I13 | protein_coding | tolerated(0.79) | benign(0) | TCGA-EJ-A7NM-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Unknown | Unknown | SD |
ABHD8 | SNV | Missense_Mutation | c.700A>G | p.Met234Val | p.M234V | Q96I13 | protein_coding | tolerated(0.48) | benign(0) | TCGA-G9-6329-01 | Prostate | prostate adenocarcinoma | Male | >=65 | 7 | Unknown | Unknown | SD | |
ABHD8 | SNV | Missense_Mutation | c.995N>C | p.Asn332Thr | p.N332T | Q96I13 | protein_coding | tolerated(0.07) | benign(0.417) | TCGA-HC-A4ZV-01 | Prostate | prostate adenocarcinoma | Male | <65 | 9 | Unknown | Unknown | SD | |
ABHD8 | SNV | Missense_Mutation | c.355N>A | p.Val119Met | p.V119M | Q96I13 | protein_coding | tolerated(0.08) | benign(0.003) | TCGA-BR-7959-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Chemotherapy | etoposide | CR |
Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |